Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AUSTIN, Texas, May 1, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and women’s health, will hold a conference call on Wednesday, May 15, 2013, at 4:30 p.m. Eastern time to discuss results for the first quarter ended March 31, 2013. Financial results will be issued in a press release prior to the call.
Vermillion’s President and CEO Thomas McLain will host the call, followed by a question and answer period.
Date: Wednesday, May 15, 2013
Time: 4:30 p.m. Eastern time (3:30 p.m. Central time)
Dial-In number: 1-800-709-0218
International: 1-212-231-2915
Conference ID: 21656230
Webcast: http://www.media-server.com/m/p/mo7xofgw
The conference call will be webcast live and available for replay via the investor section of the company’s website at www.vermillion.com.
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available approximately two hours after the call through May 29, 2013.
Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay ID: 21656230
About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women’s health. Additional information about Vermillion can be found at www.vermillion.com.
Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 1-949-574-3860
vrml@liolios.com
SOURCE Vermillion, Inc.
Help employers find you! Check out all the jobs and post your resume.
